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Introduction Search strategy
The search strategy was that adopted by the Peripheral
The following abstracts are part of an ongoing quar- Vascular Diseases Collaborative Review Group.
terly series of articles produced by the Cochrane Col-
Selection criterialaborative Review Group on Peripheral Vascular
Randomised controlled trials in which patients re-Diseases. The reviews are published in full on the
ceiving a femoropopliteal graft received autologousCochrane Library, a quarterly electronic journal avail-
vein, Dacron, polytetrafluoroethane (PTFE), humanable on CD-ROM. This format allows Cochrane re-
umbilical vein (HUV) or composite grafts.views to accommodate new data, as it becomes
available, making the library a consistently up-to-date Data collection and analysis
source of information over time. Nine trials were included, with 1334 participants. Out-
If you are interested in writing a Cochrane review comes included primary and secondary graft patency,
or becoming a member of the Peripheral Vascular survival with intact limb, use of resources and com-
Diseases Group please contact: plications.
Professor F. G. R. Fowkes,
Main resultsCochrane Collaborative Review Group on
In one trial of above-knee grafting, primary and sec-Peripheral Vascular Diseases,
ondary patency were significantly better for saphenousDept. of Public Health Sciences,
vein (73% and 90% respectively) compared to PTFEUniversity of Ediburgh,
(47% and 47%) and Dacron (54% and 60%) at fourTeviot Place,
years.Edinburgh EH8 9AG,
Two trials comparing in situ and reversed saphenousU.K.
vein grafts to the popliteal artery revealed no dif-Tel. +44 (0) 131 650 3220
ferences in primary patency (64% and 62% re-Fax. +44 (0) 131 650 6904
spectively), secondary patency (65% and 70%), orE-mail: gerry.fowkes@ed.ac.uk
survival with intact limb (74% both groups) with five-Any comments or criticisms on Cochrane PVD re-
to ten-year follow-up.views/abstracts should be made through the com-
Three trials comparing PTFE with HUV for femoro-ments/criticisms facility on the Cochrane Library, or
popliteal grafting showed significantly better sec-by contacting the group directly at the above address.
ondary patency rates for HUV; one also showed sig-
nificantly better primary patency for HUV at five years.
Comparison of PTFE grafts with, and without, a
vein cuff found no difference in above-knee grafts;
Abstracts
however, primary patency below-knee was higherAbstract: Graft Type for Femoropopliteal Bypass
with a PTFE plus vein-cuff bypass (52% vs. 29%, p=Surgery
0.03) at two years.N. Mamode and R. N. Scott
Date of most recent substantive amendment: 24 December
Conclusions1998
There is no clear evidence that autologous vein is best
for femoropopliteal grafting. In terms of patency, inObjectives
To determine the most effective graft type for treatment situ and reversed vein grafts are equally successful,
while HUV performs better than PTFE. A distal veinof occlusion of the femoropopliteal arterial segment.
Outcomes include: overall success of grafting (patency cuff may improve primary patency for below-knee
PTFE femoropopliteal grafts.and limb salvage), complications, and use of resources.
1078–5884/99/040281+02 $12.00/0 Ó 1999 W.B. Saunders Company Ltd.
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Abstract: Steroid Sex Hormones in the Treatment of Data collection and analysis
Four trials appeared to meet the inclusion criteria, butLower Limb Atherosclerosis
one was excluded because of poor methodology andJ. F. Price and G. C. Leng
another is awaiting translation into English. The twoDate of most recent substantive amendment: 13 June 1998
remaining trials compared testosterone treatment with
placebo in a total of 83 men with intermittent clau-Objectives
dication. A variety of outcome measures wereTo determine the effectiveness and safety of steroid
reported, including subjective improvement in symp-sex hormones in the treatment of lower limb athero-
toms and measures of walking distance. Outcomes forsclerosis in terms of alleviating symptoms, preventing
overall mortality and cardiovascular events were notdeterioration of underlying disease and reducing over-
included in these short trials. Data was extracted in-all mortality.
dependently by the reviewers and, where possible,
trial results were combined by meta-analysis.Search strategy
Randomised controlled trials of steroid sex hormones Main results
in lower limb atherosclerosis were sought through Testosterone therapy produced no improvement in
computerised searches of EMBASE and MEDLINE, tests of walking distance or in a variety of other
objective tests for peripheral arterial disease, includingand by hand-searching relevant journals, using the
venous filling time, muscle blood flow and plethys-search strategy described by the Peripheral Vascular
mography. The odds ratio for subjective improvementDiseases Review Group.
in symptoms using the combined trial results was also
non-significant (OR 1.27, 95% CI 0.48 to 3.33).Selection criteria
All randomised controlled trials of steroid sex hor- Conclusions
mones in the treatment of lower limb atherosclerosis There is no evidence to date that short-term tes-
were included. Studies of participants with inter- tosterone treatment is beneficial in male subjects with
mittent claudication, critical leg ischaemia or with lower limb atherosclerosis. However, this might reflect
asymptomatic lower limb atherosclerosis who were limited data rather than the lack of a real effect. No
treated with steroid sex hormones, either oestrogenic trials are available which investigated the potentially
or androgenic, were eligible for inclusion. Trials were beneficial effects of oestrogenic hormones in women
with lower limb atherosclerosis.selected by JFP and checked by GCL.
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